Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus ETHRIL 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus ETHRIL 500.
AZASITE vs ETHRIL 500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Acetaminophen (paracetamol) is a central analgesic and antipyretic agent whose exact mechanism is not fully understood but is thought to involve inhibition of cyclooxygenase (COX) enzymes in the brain, primarily COX-2, and activation of descending serotonergic pathways. It has weak peripheral anti-inflammatory activity.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
500 mg orally every 6 hours as needed for pain. Maximum daily dose: 2000 mg.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 6-12 hours in hepatic impairment or overdose.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Renal excretion of unchanged drug and glucuronide conjugate accounts for 90-95% of elimination; biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic